Multicenter retrospective study of adjuvant chemotherapy for adenocarcinoma of the esophagogastric junction

The incidence of adenocarcinoma of the esophagogastric junction (AEG) is increasing. The efficacy of adjuvant chemotherapy after surgery for AEG is unclear. A retrospective study at three centers in China found that after D2 gastrectomy for pathological stage II/III adenocarcinoma of the esophagogastric junction, compared outcomes of patients who did versus who did not receive adjuvant chemotherapy. Use of adjuvant chemotherapy was associated with better disease-free and overall survival. After propensity score matching the HR for DFS was 0.52 (p<0.001) and the HR for OS was 0.63 (p<0.001).